Multiparameter Flow Cytometry (MPFC) Minimal Residual Disease Status as a Prognostic Factor in Newly Diagnosed Egyptian Multiple Myeloma Patients: A 36-Month Follow-Up Study

Detection of minimal residual disease in Egyptian multiple myeloma patients by multiparametric flowcytometry

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202602521522057

Enrollment

102

Registered

2026-02-26

Start date

2020-12-21

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

Minimal Residual Disease assessment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • Egyptians • Patients diagnosed as multiple myeloma • Male or female • Any Age group

Exclusion criteria

Exclusion criteria: • Non Egyptians • Any other malignancies

Design outcomes

Primary

Measure	Time frame
Outcome Name: Progression-Free Survival (PFS) Timeframe: 36 months Description: The time from the date of diagnosis (or start of treatment) to the date of first documented disease progression or death from any cause, compared between MRD-negative and MRD-positive patient groups as assessed by MPFC. Outcome Name: Overall Survival (OS) Timeframe: 36 months Description: The time from the date of diagnosis to death from any cause, evaluated based on the MPFC MRD status achieved.	—

Measure

Time frame

Outcome Name: Progression-Free Survival (PFS) Timeframe: 36 months Description: The time from the date of diagnosis (or start of treatment) to the date of first documented disease progression or death from any cause, compared between MRD-negative and MRD-positive patient groups as assessed by MPFC. Outcome Name: Overall Survival (OS) Timeframe: 36 months Description: The time from the date of diagnosis to death from any cause, evaluated based on the MPFC MRD status achieved.

—

Secondary

Measure	Time frame
Outcome Name: Rate of MRD Negativity. Timeframe: At the time of MRD assessment (e.g., post-induction)Description: The percentage of patients who achieved undetectable minimal residual disease (MRD negativity) using Multiparameter Flow Cytometry (MPFC) with a sensitivity of at least 10-4.	—

Countries

Egypt

Contacts

Public ContactSally Ibrahim

National Cancer Institute Cairo University

sally.ibrahim@nci.cu.edu.eg+201007917157

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026